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Summary Overexpression of the multidrug resistance (mdrl) gene has been implicated in resistance to a
number of the chemotherapeutic agents currently used in the treatment of bladder cancer (doxorubicin,
vincristine and epirubicin). We report the development and validation of a quantitative assay for the
determination of mdrl gene transcript levels based on reverse transcription and the polymerase chain reaction
(PCR), sensitive to less than 2-fold variations in transcript levels. Using these techniques, mdrl mRNA levels
were investigated in 32 primary untreated transitional cell carcinomas of the bladder. mdrl mRNA was
detected in all samples, with levels varying between individual tumours over a 63-fold range. These variations
were not associated with the proliferative status of the tumour. mdrl mRNA levels were significantly higher in
poorly differentiated high-grade (G3) tumours than in well- and moderately differentiated low-grade (GI and
G2) tumours (P = 0.0057). The results suggest that this relationship may extend to mdrl mRNA levels being
an indicator of poor prognosis, as anticipated on the basis of the observed relationship to tumour stage and
grade. No evidence was found to implicate mdrl mRNA levels as a predictor of tumour recurrence or
progression. Given that mdrl mRNA levels are increased in a proportion of high-grade bladder tumours that
are routinely subjected to chemotherapy, we discuss the possibility that mdrl mRNA levels may be clinically
significant as determinants of chemotherapeutic response and outcome in bladder cancer.
Cancer of the urinary bladder is the fifth most common
malignancy in males of the western world, approximating to
16 new cases per 100,000 males per year in western popula-
tions (Davies, 1982). Transitional cell carcinomas (TCCs) of
the urothelium constitute more than 90% of urothelial malig-
nancies (Raghavan, 1988). Well-differentiated superficial
tumours make up 60-65% of the bladder TCCs and may be
treated by local resection with 5 year survival of 80%
(Raghavan, 1988; Kiemeney et al., 1993). However, the prog-
nosis for patients presenting with muscle-invasive,
dedifferentiated tumours is poor, with typical survival rates
of 40-50% following combination radiotherapy and radical
cystectomy (Skinner & Lieskovsky, 1984; Hendry, 1988).
Systemic chemotherapy is increasingly being used in the
treatment of invasive bladder cancer, with combination
regimens proving the most successful. Using an MVAC
(methotrexate, vinblastine, doxorubicin, cisplatin) regimen,
Sternberg et al. (1988) achieved a 67% response rate (37%
complete) with median remission of over a year. Similarly,
Harker et al. (1985) produced a 56% total (28% complete)
response rate with median survival of 8 months using a CMV
regimen. Both studies showed responses at all sites of the
disease. However, it is clear that invasive tumours of the
bladder are not wholly responsive to chemotherapy, with
the majority of patients still dying of their disease. The
reasons for this remain unclear - several cellular mechanisms
have been described that may confer upon tumours resistance
to many of the currently used chemotherapeutic drugs, of
which the multidrug resistance (mdrl) gene has been the most
widely studied to date.
Classical multidrug resistance is manifested by cross-
resistance to a number of functionally unrelated lipophilic
drugs of little structural similarity, including the vinca
alkaloids (vincristine, vinblastine), the anthracyclines (doxo-
rubicin, epirubicin), antibiotics (actinomycin D, mitomycin
C) and taxol, and is thus implicated in resistance to a
number of the agents currently used in the treatment of
invasive bladder cancer. Acquisition of a multidrug resistance
phenotype has been causally associated with expression of
the mdrl gene, which encodes P-glycoprotein (PGP), a
170 kDa plasma membrane protein that functions as an
energy-dependent drug efflux pump resulting in decreased
drug accumulation (Endicott & Ling, 1989; Van der Bliek &
Borst, 1989). Cell line studies have shown good correlation
between mdrl mRNA levels and the degree of multidrug
resistance (Shen et al., 1986; Fojo et al., 1987; Chan et al.,
1988; Noonan et al., 1990).
mdrl expression has been widely observed in many differ-
ent human tumour and tissue types, with increased mdrl
levels frequently observed at relapse following chemotherapy
(Fojo et al., 1987; Goldstein et al., 1989; Noonan et al.,
1990). Intrinsic variation in mdrl expression levels may be an
important determinant of tumour response, yet few studies
have investigated variation of mdrl mRNA levels within a
specific tumour type prior to treatment, or related this to
factors such as tumour grade and survival. Undetectable or
low levels of mdrl mRNA have been reported in both drug-
sensitive and drug-resistant tumours prior to chemotherapy,
lying close to or below the detection limits of conventional
methods (Goldstein et al., 1989; Noonan et al., 1990). In
bladder neoplasia, detection rates in untreated tumours have
been mixed; at the protein level, Naito et al. (1992) reported
detectable PGP in 32% of tumours by immunohistochemis-
try, while Benson et al. (1991) reported PGP expression in
71% of tumours using flow cytometry methods. At the mes-
sage level, Goldstein et al. (1989) using Northern blot
analysis reported only one weakly mdrl mRNA-positive
bladder tumour in six analysed. No previous studies have
systematically investigated mdrl mRNA expression in blad-
der cancer.
Assay insensitivity coupled with the often limited sample
material available from tumours has hampered the detection
of what may be clinically significant levels of mdrl mRNA.
To investigate whether such mdrl mRNA levels lie below
these detection limits, we report the development and valida-
tion of an assay based on reverse transcription and the
polymerase chain reaction (PCR) for use in the determina-
tion of mdrl mRNA levels in clinical samples. Using these
methods we have determined the incidence of and variation
in mdrl transcript levels in a series of untreated TCCs of the
bladder, and investigated the relationship of these levels to
tumour stage, grade and rate of proliferation, prognosis,
survival, progression and recurrence.
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Materials and methods
mdrl transcript levels were measured relative to those of 18S
ribosomal RNA as an internal reference. The MHC class II
related protein, P2-microglobulin (02-M), has previously been
used as an internal reference for the determination of mdrl
transcript levels by polymerase chain reaction (PCR)-based
methods (Kuwazuru et al., 1990; Noonan et al., 1990). We
have also investigated the suitability ofP2-M mRNA levels as
an internal reference for the measurement of mdrl mRNA
levels in bladder cancer.
Tumours and tissues
TCC tumour samples obtained at resection or cystectomy
were immediately snap frozen in liquid nitrogen and transfer-
red to a - 80°C freezer for storage. A portion of the sample
was sent for histological assessment and the tumours were
staged and graded according to UICC (1978) criteria. All
samples described in this study had not received prior
chemotherapy. Eleven out of 18 of the patients with invasive
tumours (T2-T4) went on to undergo chemotherapy.
Adrenal tissue was obtained from patients undergoing radical
nephrectomy.
Care was taken to limit the proportion of the tumour
sample contaminated by normal tissue. Because of their
papillary growth pattern superficial tumours were readily
removed without contamination from underlying normal tis-
sue. Although the invasive tumours were more difficult to
separate from the underlying lamina propria and muscle,
contamination by normal tissue was minimised by only tak-
ing samples from the protruding mass of the tumour.
Although it was difficult to ensure complete elimination of
normal tissue from these samples, histological examination
indicated an upper limit of 10-15% normal tissue.
Cell lines
Multidrug-resistant cell lines known to overexpress the mdrl
gene and their parental controls were used for assay develop-
ment and validation. All lines were tested and found to be
mycoplasma negative.
The KK47 cell line was established from an untreated
grade 1, stage Ta TCC of the bladder, from which the
multidrug-resistant cell line KK47/ADM was derived by
stepwise selection in increasing concentrations of doxorubicin
(Kimiya et al., 1992). Both lines were grown as monolayer
cultures in complete minimum essential medium (MEM) at
37°C in a 5% carbon dioxide atmosphere, and subcultured
weekly by harvesting with a 0.25% trypsin - 0.02% EDTA
solution and reseedingy at 3 x 106cells per 175 cm2 flask.
The small-cell lung cancer (SCLC) cell line NCI-H69P was
derived from a patient who had previously received multi-
drug therapy. Its multidrug-resistant variant, H69/LX4, was
derived by stepwise selection in doxorubicin (Twentyman et
al., 1986). Both lines were cultured in RPMI-1640 medium
(Dutch modification) (Northumbria Biochemicals) supple-
mented with 10% fetal calf serum, L-glutamine (2 mM),
penicillin (100 U ml-1) and streptomycin (100jigml-') at
37°C in a 5% carbon dioxide atmosphere. Doxorubicin
(0.4iLgml-') was added to H69/LX4 cultures. Both lines
were grown as non-adherent batch cultures, and resuspended
in fresh medium every 4 days.
RNA extraction
Total RNA was extracted from the remaining tumour tissue
and cell lines using the RNAzol method (Chomzynski &
Sacchi, 1987). Briefly, in the case of solid tumours, tissue was
pulverised in liquid nitrogen and rapidly lysed in a phenol-
guanidinium thiocyanate-i-mercaptoethanol mixture. Cell
lines were harvested at 70% confluence by scraping in ice-
cold phosphate-buffered saline (PBS) (KK47 and KK47/
ADM) or by centrifugation followed by washing in PBS
(H69 and H69/LX4). Both methods preceded direct lysis as
described. RNA was isolated by chloroform extraction and
precipitated by isopropanol addition. Following washing in
ethanol and resuspension in sterile water, RNA yield and
purity were checked by spectrophotometric determination at
260 nm and 280 nm and the integrity assessed by electro-
phoretic size separation on 1.4% agarose gels.
cDNA synthesis
First-strand cDNA was synthesised from total RNA by
reverse transcription using the random primer extension
method. A 10fig aliquot of total RNA was heated to 100°C
for 5 min, then added to a 200fLI reaction (final volume)
consisting of the following: pd(N)6 random hexamers (0.88
units; Pharmacia), dithiothreitol (0.01 M; Gibco, BRL),
dATP, dCTP, dTTP and dGTP (1 mM each; Pharmacia),
Moloney murine leukaemia virus reverse transcriptase (1200
units, Gibco BRL) and human placental RNAse inhibitor
(35 units; Gibco BRL) made up in 1 x reverse transcriptase
buffer (Gibco BRL). The reaction was allowed to proceed at
37°C for 1.5 h before termination by heating to IOOC for a
further 5 min. Following synthesis, cDNA was purified by
passage through a cDNA spun column containing Sephacryl
S-300 (Pharmacia) to remove any remaining proteins, free
nucleotides and random hexamers remaining from previous
procedures. The second cDNA strand was synthesised by the
extension of sequence-specific oligonucleotide primers in the
first cycle of a subsequent polymerase chain reaction.
Optimisation ofthe polymerase chain reaction
mdrl and P2-M primers chosen were those used by Noonan
et al. (1990). The mdrl primers distinguish between the mdrl
and mdr2 gene sequences, and both the mdrl and P2-M
primers span an intron to control against contamination by
amplification of genomic DNA sequences. Primers to 18S
rRNA were chosen using a computer program designed by
Lowe et al. (1990) - ATGCTCTTAGCTGAGTGTCC and
AACTACGACGGTATCTGATC (residues 763-782 and
1055-1074 respectively; Gonzalez & Schmickel, 1986).
Primers were made on an oligonucleotide synthesiser (Model
392, Applied Biosystems). The primers yielded products of
167 base pairs (mdrl), 120 base pairs (02-M) and 311 base
pairs (18S rRNA). For each set of primers, a series of
fixed-condition PCR reactions were performed employing a
fixed concentration of input cDNA. The absolute magnesium
chloride concentration was varied in 0.5 mM steps in the
0-5 mM range. The optimal magnesium chloride concentra-
tions were determined to be: mdrl, 2.5 mM; P2-M, 3 mM; and
18S rRNA, 1 mM.
Determination ofmdrl mRNA levels
Typical PCR reaction yields for various cDNA inputs are
shown in Figure 1. An initial range-finding experiment was
performed to determine the range of serial cDNA dilutions
over which PCR amplification is linear for each target
species. Serial cDNA dilutions for each species are simul-
taneously and independently amplified over 25 PCR cycles
(94°C for 1 min, 56°C for 1 min, 72°C for 1 min) using other-
wise fixed reaction conditions. A 25gil reaction consisted of
the following (final concentrations are stated): 10gIl of appro-
priate cDNA dilution, Taq polymerase (0.75 units; Advanced
Biotechnologies), dNTPs (0.25 mM dTTP, dCTP and dGTP,
0.125 mM dATP; Pharmacia), 0.25 gil of [X32P]dATP (Amer-
sham), oligonucleotide primers (0.48 giM each) and the
magnesium chloride component (2.5 mM mdrl, 3 mM 1P2-M
and 1 mM 18S rRNA; Advanced Biotechnologies), made up
in a final concentration of 1 x PCR reaction buffer
(Advanced Biotechnologies), and overlaid with mineral oil.
Following amplification, 10gil aliquots were analysed by elec-
trophoretic separation on 12% polyacrylamide gels at 100 V
for 1.5 h. Gels were dried under heat and vacuum and the
radioactively labelled PCR products detected and analysed
using a PhosphorImager (Molecular Dynamics). A typical682 S.C. CLIFFORD et al.
autoradiograph image of the separated prod,ucts is shown in
Figure 1. For each species, the amount of PCR product
(measured as incorporated radioactivity) was plotted against
input cDNA dilution (see Figure 2). Regression analysis was
performed on the points constituting the linear range of
amplification for each species. The ratio of input total cDNA
concentrations (X,/X2 in Figure 3) for a given yield in the
linear range of amplification is a measure of the ratio of
cDNA concentrations present for each species. This is equal
to the slope ratio (M1/M2) for the regression lines on the
linear part of the yield curve (see Figure 3). Thus, mdrl
mRNA levels were expressed as an mdrl/18S ratio. Subse-
quent replicates were performed using only four serial dilu-
tions (lying within the predefined linear amplification ranges)
per species. Analysis was performed in triplicate on all sam-
ples. A linear regression correlation coefficient (r2) of greater
than 0.95 was used as the criterion for accepting data that
fell within the linear range of amplification.
Determination oftumourproliferative status - MIBI analysis
The monoclonal antibody MIBI reacts with the human
nuclear cell proliferation-associated antigen recognised by the
monoclonal antibody, Ki67, that is expressed in all active
parts of the cell cycle (Cattoretti et al., 1992). The extent of
MIB1 staining was thus used to assess the proliferative status
of a tissue.
Paraffin sections (4pim thick) were taken and dewaxed in
xylene prior to rehydration through alcohol and water. Sec-
tions were treated with 0.1 M citrate buffer (pH 6.0) and
microwaved for 20 min. Endogenous peroxidase activity was
blocked by prior treatment with 3% hydrogen peroxide. The
sections were then rinsed in Tris-buffered saline (TBS pH 7.6)
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Figure 1 Products produced from simultaneous independent
amplification over 25 PCR cycles of serial cDNA dilutions
derived from a bladder tumour sample for mdrl, 12-M and 18S,
following separation by polyacrylamide electrophoresis and
visualisation by autoradiography.
for 2 min, followed by normal goat serum (Life Science).
Sections were incubated with MIB1 antibody (The Binding
Site) (diluted 1:50) for 60 min, washed again and peroxidase
activity developed using biotinylated goat anti-mouse/rabbit
secondary antigen (Dako) for 30 min. After further washing
in TBS, sections were incubated in streptavidin AB complex/
horseradish peroxidase (Dako) for 30 min. Sections were then
incubated in diaminobenzidine solution for 10 min, washed
and counterstained in Carruzi's hamatoxylin, dehydrated and
mounted. A negative control was performed for each tissue
section by omission of primary antiserum. Tonsillar tissue
was used as a positive control. The proportion of tumour cell
nuclei staining with MIBI was assessed in random fields from
well-preserved areas of tumour. A minimum of 2,000 cells
were counted in each case. Nuclei in morphologically malig-
nant cells were considered positive when dark-brown nuclear
staining was observed.
Results
Assay validation
For any given tumour RNA sample, the standard error of
the mean based on the repeat experiments was typical-
ly ± 23% of the mean value. Experiments performed on the
H69/LX4 cell line indicate that three separate analyses of a
sample utilising independent cell cultures, RNA extractions
and cDNA syntheses produces results (mdrl/18S ratios) lying
within a range of 1.807 ± 0.911 x l0-' (mean ± s.d.).
To examine any influence that PCR amplification efficiency
may have on our results, efficiency studies were performed on
four different tissue types with varying mdrl/18S levels.
Figure 4a and b shows the results for a typical bladder
tumour RNA sample as an example. Reaction efficiency was
calculated using the formula Nn = N_I (1 + a), where Nn is
the amount of product after the nth cycle, n is the cycle
number and a is the efficiency. 18S rRNA was amplified
with the greatest efficiency, followed by mdrl then P2-M
(Figure 4b). This order of efficiency remained constant for
tissues analysed. For each product species, the absolute
amplification efficiency showed some variation between
samples, however relative amplification efficiencies remained
consistent between samples, irrespective of tissue type or level
of mdrl expression (Table I). The maximum efficiency range
corresponds to the linear range of amplification, and its posi-
tion is dependent on the input cDNA concentration. The assay
that we have described utilises cDNA concentrations in the
range that gives linear amplification over 25 PCR cycles.
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Figure 2 Graph showing a log-log plot of product produced
versus initial amount of input cDNA for the three series of points
shown in Figure 1. The linear ranges of amplification used in
subsequent quantifications are highlighted for each species by
black arrows. Note that these ranges lie between the ranges of
reaction threshold and saturation. A, mdrl; 0, P2-M; 0,
18S.
Figure 3 Illustration showing the calculation of relative mRNA
levels for two gene product species. Lines labelled 'Gene products
1 and 2' represent the linear ranges of amplification for two given
species, extrapolated through the origin. In the linear
amplification range, the ratio of input cDNA for a given product
(Xl/X2) is a measure of the relative amounts of mRNA for the
two genes under consideration. For common extrapolation
through zero, this is equal to the slope ratio (M/AM2) for the two
lines.
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utilises cDNA concentrations in the range that
amplification over 25 PCR cycles.
P2-Microglobulin as an internal reference
P2-M mRNA levels in individual bladder tumour
to vary over a 140-fold range when measured re
rRNA. Similarly, mdrl mRNA levels measure(
P2-M did not correlate with those measured re]
rRNA (r2 = 0.017). Thus P2-M transcript levels
between bladder tumour samples and were th
sidered unsuitable as an internal reference. Fo
analyses mdrl mRNA levels were expressed as r
to 18S rRNA.
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Figure 4 a, A PCR efficiency study performed c
tumour sample (mdrl/18S ratio = 3.4 x 10-6). me
cDNA dilution), P2-M (0, 10-' dilution) and 1I
dilution) were amplified over 33 PCR cycles and pi
mined at alternate cycles between cycles 15 and 32
shown plotted against cycle number (linear scale
typical PCR reaction kinetics of (1) a detection thrl
early cycles, (2) a linear range of amplification and (
saturation plateau in the later cycles. b, Changes
efficiency over subsequent PCR cycles for the analy
a. For each product species, efficiency (I = 100%);
the text is plotted against cycle number. Graphs pr
efficiency rising to a peak that corresponds to the lir
amplification, then tailing off as the reaction rea
tion.
gives linear
s were found
lative to 18S
T2, n=2; T3, n=9; T4, n=6; by grade, GI, n=2; G2,
n 12; G3, n = 18), with a mean mdrl/18S ratio of 7.34 x 10-6.
A 63-fold variation in mdrl/18S levels was observed between
individual tumours (highest 3.4 x 10-5; lowest = 5.4 x
l0-7).
d relative to Relationship ofmdrl mRNA levels to stage andgrade
lative to 18S mdrl/18S ratios were significantly higher in poorly
,vary widely differentiated high-grade (G3) than in well- and moderately
ierefore con- differentiated low-grade (GI and 2) tumours (Figure 5). The
r subsequent pooled mdrl/18S mean ±
s.e. for grades GI and G2 com-
atios relative bined was 3.41 ± 0.53 x 106 compared with 10.40 ± 2.2 x
106 for the G3 tumours (t-test, P = 0.0057). No low-grade
tumours showed high mdrl levels, and while not all high-
grade tumours showed elevated mdrl/18S ratios there was a
markedly increased incidence of high-expressing tumours in
9our samples this group (Figure 5). With the exception of single his-
9; T1. n = 6: tologically atypical tumour which presented as TI G3 (car-
cinoma in situ), all superficial tumours (Ta and TI) were also
low grade, while all invasive tumours (T2, T3 and T4) were
high grade. Thus, the mdrl expression pattern observed for
a tumour grade essentially extends to tumour stage; based on
pooled means, mdrl/18S ratios were marginally significantly
higher (P = 0.085) in muscle-invasive tumours than in
superficial, non-invasive tumours. Removal of the atypical
carcinoma in situ sample from the analysis increases the level
of significance (P = 0.012). The two normal tissue samples
examined showed higher levels of mdrl mRNA than the
superficial tumour group and the levels were similar to those
seen in the high-grade invasive tumours.
31 33
Relationship between mdrl expression andprogression,
b recurrence andsurvival
For these analyses, tumours were split into high-mdrl
mRNA level (mdrl/18S ratio > 1 x 10', n = 8) and low-
mdrl mRNA level (mdrl/18S ratio <9.99 x 10-6, n = 24)
groups. This distinction was made on the basis of the dis-
tribution of expression observed, with all high-mdrl mRNA
tumours lying outside the main cluster of points.
No evidence was found to implicate mdrl mRNA levels as
a predictor of tumour recurrence or progression. No correla-
tion (r
= 0.08, n = 13) existed between mdrl/18S ratios and
9-31 31-33 the rate of recurrence. Forty-three per cent (three of seven)
high-mdrl-expressing tumours underwent progression, com-
pared with 33% (4 of 12) of low-mdrl-expressing tumours.
)n a bladder There was no significant difference between these incidences
drI (A, 100 of progression (Fisher's exact test, P = 0.35). Of patients with
gS (0, 1o-4 tumours with low mdrl mRNA levels, 64% (14 of 22) were
roduct deter- still alive at the end of their current follow-up period, com-
3. Product is pared with 25% (2 of 8) of high-mdrl mRNA-expressing
i). Note the tumours. The minimum follow-up period was 32 months,
eshold in the with all deaths occurring within 72 months of biopsy. Only
(3) a reaction patients dying from their disease were included in the
;sis shown in analysis, regardless of treatment received. Log-rank survival
as defined in analysis (Peto et al., 1977) showed no significant difference
oduced show (P = 0.36) between survival for the groups of tumours with
near phase of high and low mdrl mRNA levels (Figure 6). However, con-
Lches satura- tingency table analysis using Fisher's exact test showed a
lower proportion of survivors for patients with high mdrl
Table I The results of amplification studies on the four different tissues.
Relative amplification efficiencies between product species are shown
(NA = results not available)
PCR amplification efficiency ratios
Tissue type mdrl/18S Ratio mdr1/P2yM mdrl/18S P2-M/18S
H69/LX4 2.8 x 10-3 1.14 0.875 0.77
Adrenal 2 x 10-4 1.19 NA NA
Normal bladder 3.9 x 10-5 1.16 0.88 0.75
Bladder tumour 3.4 x 10-6 NA 0.94 NA
,.L L
V
I
)_684 S.C. CLIFFORD et al.
60
50-
40-
30-
20
10 T
0-
Normal Ta Ti T2 T3 T4
Figure 5 Individual tumour mdrl mRNA levels measured rela-
tive to 18S rRNA [shown as mean mdrl/18S ratio (± standard
error), n ) 3]. Tumours are shown grouped by stage of progres-
sion and the histological grade is indicated by shading: open,
normal bladder; single-hatched, G1; cross-hatched, G2; solid, G3.
Note the increased incidence of higher expressing tumours in the
high-grade group.
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Figure 6 Log-rank survival curves for groups of patients with
tumours expressing high and low mdrl mRNA levels. Each death
is represented by a vertical drop on the graph. Surviving patients
are shown as a vertical tick on the graph representing the end of
their current follow-up period. The log-rank test gave P = 0.36
for no difference in survival rates between the low- (-) and
high-mdrl ( ) mRNA groups (see also text).
mRNA tumours, which was marginally significant
P= 0.07).
Relationship between mdrl mRNA levels and tumour
proliferative status
The percentage of proliferating cells within the tumours
studied (those displaying the Ki67 antigen) did not correlate
with their mdrl/18S ratios (r = 0.06, n = 24).
Other mdrl mRNA determinations
As part of general method validation and to put our data
into a broader context, mdrl/18S ratios were also determined
for some other tissues and cell lines with known low and
high levels of mdrl expression. Adrenal tissue had an mdrl
mRNA level (mdrl/18S = 2.00 x 10-4) approximately 27
times higher than the mean level of expression in bladder
tumours. Hyperexpression (1.58 x 10-3) was detected in the
mdr SCLC cell line H69/LX4, while no mdrl expression
could be quantified in its drug-sensitive parent line H69 at 25
PCR cycles. The mdr bladder tumour cell line KK47/ADM
had 157-fold overexpressed mdrl mRNA levels (mdrl/18S
ratio 3.88 x 10-4), compared with levels of 2.46 x 10-6 in its
parental line KK47.
Discussion
The PCR-based transcription assay
Measurement of expression relative to an endogenous inter-
nal reference avoids the need for addition and quantification/
titration of an external reference standard, or the manipula-
tion of products post amplification to distinguish them (e.g.
the presence of restriction enzyme cleavage site in a synthetic
reference standard), both strategies being among those
previously described (Becker-Andre & Hahlbrock, 1989;
Wang et al., 1989). 18S rRNA is widely used to control for
equal loading and transfer in Northern blot methods for
RNA analysis. Good evidence exists for the use of rRNA (of
which 18S rRNA is one component) as a reference. While
variations in total rRNA levels per cell do occur, these are
usually accompanied by an equal fluctuation in total mRNA
levels (Johnson et al., 1976). Hirsch (1967) observed consis-
tent rRNA levels (80% of total) in normal rat liver, fasted
rat liver (with a 50% reduction in total RNA content) and
rapidly dividing rat hepatoma. P2-Microglobulin has been
commonly used as an internal reference for the determination
of mdrl transcript levels in PCR-based studies (Kuwazuru et
al., 1990; Noonan et al., 1990). However, our studies have
demonstrated a 140-fold variation in P2-M mRNA levels
between individual bladder tumours, rendering it completely
unacceptable for such a purpose. Whether these observations
extend to other tumour systems remains to be investigated.
Amplification of target and reference from a common cDNA
source controls for variations in efficiency of both RNA
extraction and cDNA synthesis. Our efficiency studies
indicate that, while absolute amplification efficiencies vary
between different species, their relative efficiencies remain
constant regardless of tissue type or mdr1/18S ratio and thus
have no influence on the results observed.
Based on the typical standard error of 23% of the mean of
three replicates, this assay is capable of discriminating 1.6-
fold differences in mRNA levels between samples at the 95%
confidence level. The reproducibility studies based on three
independent batch cultures, RNA extractions and cDNA
syntheses similarly indicate that mdrl mRNA levels from
three independent analyses of a given sample fall within a
2.5-fold range, however this may overestimate the situation
since the batch cultures were not harvested at uniform cell
densities and may also be prone to differing culture condi-
tions, both of which may affect cellular mRNA levels. These
limits are small compared with the 63-fold variation that we
have observed in mdrl mRNA levels between individual
tumour samples.
For the assay as described, 10lg of total RNA yields
sufficient cDNA to perform at least five replicates of the
assay, although there are various ways in which the sen-
sitivity could be further increased if necessary. In com-
parison, Northern blot analysis may require 10-20 pig of
RNA for a single analysis. In the clinical situation, in which
sample material is often limited, this may not allow for a
repeat analysis. This method offers notable improvements in
sensitivity over conventional methods, detecting mdrl tran-
script in all samples analysed, whereas previous studies using
Northern blot analysis have only detected mdrl mRNA
positivity in one of six (<17%) bladder tumours (Goldstein
et al., 1989). In this context, categorisation of samples as
mdrl mRNA positive/negative is misleading since the distinc-
tion is made by the arbitrary detection threshold of a partic-
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ular technique rather than the position of the data within a
distribution.
As with Northern blot methods, the heterogeneous nature
of tumours is one potential problem in this type of analysis.
The assay provides an overall mean mRNA level for the
whole sample analysed. It is therefore essential that the
tumour sample used is representative of the entire sample.
To test the ability of the assay to detect differences in mdrl
mRNA levels, we examined adrenal gland as an example of a
high-expressing tissue, and also multidrug-resistant lung and
bladder tumour cell lines known to overexpress P-glyco-
protein. Adrenal gland tissue has been widely reported to
have high levels of mdrl mRNA (Fojo et al., 1987; Noonan
et al., 1990). Noonan et al. (1990) reported a single bladder
tumour to have mdrl mRNA levels 68 times lower than those
in adrenal tissue. This is in agreement with our study, which
shows the mean bladder tumour mdrl/18S ratio to be 27
times lower than that of an adrenal sample. Likewise, the
mdrl/18S ratio for the KK47 cell line, derived from a super-
ficial bladder tumour, lies in the same range as all the
superficial bladder tumour samples analysed.
We have thus developed a highly sensitive and repro-
ducibly accurate PCR-based assay for the quantification of
low-level gene expression. Should it be necessary, sensitivity
of the assay could be even further improved with increased
numbers of PCR amplification cycles. Further replicates
would also increase confidence in the mean for a given
sample. This technique may be applied to the quantification
of any low-level gene expression when the cDNA sequence is
known, with the accurate quantification of results allowing a
much more detailed analysis of the data. The assay could
potentially be adapted to work at the DNA level for the
determination of gene copy numbers and levels of gene
amplification.
Variation in mdrl mRNA levels in TCC ofthe bladder
mdrl/18S ratios were found to vary over a 63-fold range in
bladder tumours. The mechanisms underlying this remain to
be elucidated. The lack of any correlation between mdrl/18S
ratios and tumour Ki67 levels indicates that the mechanism
underlying variation in tumour mdrl mRNA levels is not
simply a result of tumour proliferation or the rate of cell
turnover. Similarly, since these tumours have not been sub-
jected to selection by chemotherapy, it seems unlikely that
gene amplification plays any role in the variation of mdrl
mRNA levels observed. Transcriptional control mechanisms
have been suggested to play a significant role in the regula-
tion of mdrl mRNA levels (Goldstein et al., 1989; Zastawny
et al., 1993). Recently it has been demonstrated that wild-
type p53 protein represses human mdrl promoter activity
while mutant forms (cysteine 135 to serine) of the p53 protein
enhance mdrl transcription (Zastawny et al., 1993), thus
defining a possible mechanism for increased mdrl mRNA
levels in high-grade untreated bladder tumours, in which
frequent p53 alterations have been reported (Lunec & Mel-
lon, 1994). The stage and grade associations that we have
observed suggest that overexpression could also be a result of
the loss of genetic regulation and control associated with
high-grade (dedifferentiated) tumours. The level of mdrl
mRNA detected in normal bladder raised questions about
the contribution of normal tissue contamination to the in-
creased levels of mdrl mRNA found in the high-grade
tumours compared with the superficial group. However,
because of the careful resection technique, the maximum
observed contamination of the invasive tumours by normal
tissue of only 10-15% could not have accounted for the
elevated levels of mdrl mRNA seen in the high-grade
group.
Relationships between mdrl mRNA levels and
prognosis/survival
Our results demonstrate that mdrl mRNA levels are clearly
elevated in high-grade bladder tumours. A recent immunohis-
tochemistry study also showed increased levels of the mdrl
gene product, P-glycoprotein, in high-stage neuroblastomas
(Chan et al., 1991). Thus, evidence exists for mdrl mRNA
and P-glycoprotein levels being a marker of tumour aggres-
sion (invasiveness and dedifferentiation). However, the
majority of studies are conducted at the protein level, with
this study to our knowledge being the first to report such an
association at the mRNA level. Other studies investigating
P-glycoprotein levels in bladder cancer (Benson et al., 1991;
Naito et al., 1992) have proved inconclusive, showing no
clear relationships with stage and grade.
The population distribution ofmdrl/18S ratios observed in
bladder tumours has allowed us to distinguish groups of
high- and low-expressing tumours for use in survival analysis.
Log-rank tests showed no significant difference in survival for
either group of tumours (Figure 6), however this analysis is
complicated by the problem of non-uniform patient treat-
ment and follow-up times. The analysis by Fisher's exact test
based on proportions of survivors alone indicates a signifi-
cant relationship between high mdrl mRNA levels and poor
survival. Other studies have similarly reported high mdrl
expression to be an indicator of adverse prognosis and poor
survival in untreated tumours; at the protein level in soft-
tissue sarcomas (Chan et al., 1990), breast carcinoma (Verrelle
et al., 1991), neuroblastoma (Chan et al., 1991) and non-
lymphoblastic leukaemia (Campos et al., 1992), and at the
message level in acute myeloid leukaemia (Pirker et al.,
1991). Our results suggest that it may be worth investigating
further the prognostic potential of mdrl mRNA levels in
bladder cancer. It may be interesting to compare mdrl
mRNA with other known prognostic factors using samples
from patient groups undergoing either uniform treatment
strategies or receiving no treatment.
We have demonstrated that mdrl mRNA levels are raised
in many of the high-grade, invasive bladder tumours that are
commonly treated using chemotherapy, and suggest that the
34-fold variation in mdrl mRNA levels observed between
individual high-grade tumours could be a significant deter-
minant of their chemotherapeutic response. This is supported
by in vitro studies which show that even small variations in
mdrl mRNA levels, within the range we have observed,
result in significant differences in drug response (Noonan et
al., 1990). To evaluate the role of pretreatment mdrl mRNA
levels in the determination ofchemotherapeutic outcome, full
prospective studies have been initiated involving uniform
treatment regimens with pre- and post-chemotherapy tumour
biopsies. This will also test whether mdrl mRNA levels are
increased following treatment, as has been reported in some
tumour systems (Fojo et al., 1987; Noonan et al., 1990).
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